Valuation: BriaCell Therapeutics Corp.

Market Cap 29.82M 26M 24.27M 22.31M 41.87M 2.85B 42.87M 288M 112M 1.41B 112M 110M 4.87B P/E 2024
-2.56x
P/E 2025 -0.12x
Enterprise Value 11.95M 10.43M 9.73M 8.94M 16.79M 1.14B 17.18M 115M 45.07M 567M 44.88M 43.91M 1.95B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99.49%
Yield 2024 *
-
Yield 2025 -
1 day-0.62%
1 week-7.82%
Current month+4.09%
1 month+11.03%
3 months-12.50%
6 months-21.34%
Current year-50.71%
1 week 4.78
Extreme 4.78
5.45
1 month 4.41
Extreme 4.41
5.75
Current year 3.68
Extreme 3.68
16.5
1 year 3.68
Extreme 3.68
20.4
3 years 3.68
Extreme 3.68
1,543.5
5 years 3.68
Extreme 3.68
2,362.5
10 years 3.68
Extreme 3.68
11,250.11
Manager TitleAgeSince
Chief Executive Officer 70 01/11/2016
Director of Finance/CFO 54 01/02/2016
Chief Tech/Sci/R&D Officer 65 16/02/2022
Director TitleAgeSince
Director/Board Member 70 01/11/2016
Chairman 41 24/04/2019
Director/Board Member 74 07/03/2019
Date Insider Type Main position Quantity % Market Cap.
7/7/26 Tax

Director

45,000 0.5173%
7/7/26 Tax

Director

15,000 0.1724%
7/7/26 Option

Chief Technology Officer

28,257 0.3248%
Change 5-day change 1-year change 3-year change Capi.($)
-0.62%-7.82%-56.09%-99.61% 30.01M
+0.47%+2.03%+51.54%+70.84% 55.01B
+2.83%+0.04%+38.07%+82.59% 54.24B
+0.54%+0.67%-17.59%-13.47% 23.38B
-0.97%-5.06%+1.35%+383.00% 22.57B
+2.07%+1.44%+23.06%-9.05% 20.19B
-2.15%+0.78%+24.67%-31.03% 17.86B
-2.14%-2.72%+30.26%+536.72% 15.5B
-3.14%-8.09%+160.68%+292.18% 14.2B
-2.09%-1.41%+24.65%+178.74% 14.2B
Average -0.52%-1.23%+28.06%+139.09% 23.72B
Weighted average by Cap. +0.28%-0.20%+35.94%+130.59%

Financials

2024 2025
Net sales - -
Net income -4.79M -4.18M -3.9M -3.58M -6.73M -458M -6.89M -46.21M -18.06M -227M -17.99M -17.6M -783M -26.31M -22.94M -21.41M -19.68M -36.94M -2.52B -37.82M -254M -99.19M -1.25B -98.78M -96.64M -4.3B
Net Debt -862K -752K -701K -645K -1.21M -82.45M -1.24M -8.31M -3.25M -40.86M -3.24M -3.17M -141M -17.87M -15.58M -14.54M -13.37M -25.08M -1.71B -25.68M -172M -67.35M -847M -67.08M -65.62M -2.92B
Logo BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Employees
16
Date Price Change Volume
29/07/26 CA$4.830 -0.62% 500
28/07/26 CA$4.860 -3.57% 5,449
27/07/26 CA$5.040 +0.20% 2,277
24/07/26 CA$5.030 -3.64% 2,368
23/07/26 CA$5.220 +1.16% 2,180

Quarterly revenue - Rate of surprise